We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

Scientific concepts, discoveries, and phenomena

Rapamycin and aging biology (mechanism)

• Rapamycin (sirolimus) is discussed as a candidate for improving healthspan by modulating the mTOR pathway, particularly mTOR complex 1 (mTORC1).
• Aging in human skeletal muscle is described as involving mTOR hyperactivation / suboptimal regulation, which may impair:
  • Autophagy (recycling/clearance of damaged cellular components)
  • Protein translation (often framed as “mistranslation”)
  • Mitochondrial function (described as inefficient)
• Cycling hypothesis: Instead of continuous dosing, use rapamycin to turn down mTORC1 for a period to permit autophagy, then allow mTORC1 to rebound (often supported by exercise) to build/restore muscle components.

Why muscle function was tested (not lifespan)

• A direct human lifespan trial would be extremely long (decades).
• Muscle function is proposed as a practical proxy relevant to frailty and sarcopenia.
• The study targets older adults and focuses on measurable performance endpoints.

Clinical trial findings (human efficacy outcome)

• Participants: 40 older adults (ages ~65–85), randomized to:
  • Sirolimus/rapamycin 6 mg (once weekly)
  • Placebo
  • Both groups exercised
• Primary endpoint: 30-second chair stand test (leg strength/power measure).
  • The primary result did not reach statistical significance.
  • A trend suggested the placebo group improved more than the rapamycin group.
• Sensitivity / per-protocol analyses (pre-specified):
  • In subsets with closer adherence to protocol, results showed statistically significant blunting (attenuation) of improvement in the rapamycin arm—i.e., rapamycin underperformed placebo for chair-stand gains.
• Secondary muscle/functional measures:
  • 6-minute walk test
  • Hand grip strength
  • These also did not reach statistical significance, but directionally favored placebo > rapamycin.

Interpretation of “best of both worlds” failure

• Contrary to the cycling hypothesis, the trial did not show the intended “mTOR off then on with exercise” benefit.
• A mechanistic explanation proposed:
  • The drug’s biological activity may overlap too much with exercise sessions.
  • The reported/assumed sirolimus terminal half-life is discussed (~62 hours), raising concern that mTORC1 may still be inhibited during early exercise days after dosing.

Pharmacokinetics / dosing-cycle rationale

• Debate exists about whether serum half-life values from transplant settings apply in this context.
• A newer pharmacokinetic perspective (from an ongoing program referenced in a University of Arizona context) suggests:
  • Many people may clear rapamycin before the next weekly dose in serum (no accumulation),
  • but detectable levels may still persist on days 2–3, potentially inhibiting mTORC1 during some exercise sessions.
• Proposed remedy for future studies:
  • Longer dosing intervals (e.g., every 3 weeks or 6 weeks instead of weekly) to better separate mTOR inhibition from exercise-induced anabolic signaling.

Comparisons to prior rapamycin trials

• The discussion contrasts the trial results with the PEARL trial:
  • PEARL reportedly showed mixed outcomes, including potential body composition improvements over longer duration and different dosing/formulation approaches.
• A key difference emphasized:
  • PEARL used compounded rapamycin with formulation issues that may have reduced effective absorbed dose (e.g., lack of enteric coating leading to poor absorption).
• This trial emphasized it used non-compounded sirolimus obtained directly from Pfizer to ensure intended dosing.

Inflammation marker and adverse events

• CRP (C-reactive protein):
  • Expected to decrease with rapamycin (anti-inflammatory direction), but the study reported an opposite trend.
  • Proposed explanation: noise/outliers—two treatment participants had marked CRP elevations likely due to intercurrent issues (e.g., cough/cold, injury).
• Safety:
  • More adverse events in the sirolimus arm overall, largely muscle aches/pains attributed to the exercise protocol.
  • Notable event: one hospitalization for pneumonia occurring after a dose.
  • Because rapamycin is an immunosuppressant in transplant medicine, pneumonia risk is viewed as plausible.
• HbA1c / glucose homeostasis:
  • HbA1c showed a statistically significant increase in the sirolimus group.
  • The argued clinical significance is small, but it aligns with known rapamycin effects on glucose regulation/insulin sensitivity seen in transplant contexts.
• Overall characterization:
  • The trial is described as moderately cautionary for older adults on weekly dosing.

---

Methodology / study design (outlined)

• Study duration: 12 weeks
• Population: 40 participants, ages 65–85, not highly trained in exercise prior to enrollment
• Randomization:
  • ~Half received sirolimus/rapamycin 6 mg once weekly
  • ~Half received placebo
• Exercise intervention:
  • Home-delivered exercise bikes
  • Safety-focused protocol (avoiding high-intensity intervals for older adults)
  • Exercise days: Day 1, Day 3, Day 5
• Dosing schedule:
  • Rapamycin/placebo taken on Day 6
  • Repeat cycle across the 12 weeks
  • Rationale: dosing Saturday with expectation drug clears by Monday; results suggest this separation may have been insufficient.
• Pre-specification / rigor:
  • Endpoints and analyses were pre-registered and performed from a clinical trial database to avoid post hoc manipulation.
  • Primary analysis: intention-to-treat
  • Additional analyses: sensitivity, case-complete, and per-protocol (adherence-defined)

---

Researchers / sources featured

• Professor Matt Kaeberlein (co-author; speaker)
• Brad (host; unnamed in subtitles)
• Bonnie LaFleur (University of Arizona; referenced as running a larger trial with pharmacokinetic data)
• References to trial/source names mentioned:
  • Journal of Cachexia, Sarcopenia, and Muscle (where the results were published)
  • PEARL trial (another rapamycin study discussed for comparison)
• Pfizer (source of sirolimus used in this trial; stated to have no role in the study)
• University of Arizona (context for upcoming pharmacokinetic / dosing-frequency work)
• Joan Maddox’s study (mentioned as an example of rapamycin-related findings with different safety outcomes)